Favorable vaccine-induced SARS-CoV-2–specific T cell response profile in patients undergoing immune-modifying therapies
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.02.21.22271127: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study approval: The study protocol was reviewed and approved by Institutional Research Board of Singhealth (IRB no: 2021/2398).
Consent: All donors provided written consent for enrolment.Sex as a biological variable Patients younger than 18 years old, those with previous SARS-CoV-2 polymerase chain reaction-confirmed COVID-19, or pregnant women were all excluded. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Quantification of humoral responses: Measurements were performed using the Abbott Architect i2000 automated analyser using the SARS-CoV-2 IgG II Quant assay, a chemiluminescent microparticle … SciScore for 10.1101/2022.02.21.22271127: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study approval: The study protocol was reviewed and approved by Institutional Research Board of Singhealth (IRB no: 2021/2398).
Consent: All donors provided written consent for enrolment.Sex as a biological variable Patients younger than 18 years old, those with previous SARS-CoV-2 polymerase chain reaction-confirmed COVID-19, or pregnant women were all excluded. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Quantification of humoral responses: Measurements were performed using the Abbott Architect i2000 automated analyser using the SARS-CoV-2 IgG II Quant assay, a chemiluminescent microparticle immunoassay (CMIA) for the quantitative detection of IgG targeting the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Acquisition was performed on a BD-LSR II Analyzer (BD) within 24 hours and analysed with FlowJo software (BD) Statistics and data analysis: Statistical analyses were performed using R Statistical Software (version 4.0.3) (ggpubr::stat_compare_means) and GraphPad Prism 9. FlowJosuggested: (FlowJo, RRID:SCR_008520)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are some limitations in this study: the most important one being that the bulk of T cell experiments were performed not by direct measurement of T cell quantity, but by measuring cytokines secreted in whole blood after specific peptide stimulation. However, we provide direct evidence orthogonally that Spike-specific CD4+ and CD8+ T cells were induced by vaccination in IBD patients and visualized IL-10+ T cells. Nevertheless, while this method does not directly quantify the number of T cells, it provides a standardised method well suited for longitudinal analysis of T cell responses in patients under different treatments. The simplicity of the assay reduces the inter-assay variability, and is directly performed on fresh whole blood, limiting the detrimental effects of freezing and thawing (43). Furthermore, since T cell functionality is analysed in whole blood, the immune-modifying therapies administered into the patients are present at therapeutic levels during the assay, mimicking, as we previously argued (44), more closely the situation in vivo. In conclusion, we show here that mRNA vaccination in IBD patients under different immunomodulatory treatments triggers a robust cellular immune response amidst an attenuated humoral response. Particularly, patients under TNFi monotherapy demonstrate reduced kinetics of decline of Spike-specific T cell responses, and an ability to secrete a cytokine profile characterized by the simultaneous presence of IFN-γ, IL-2 and the anti-...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 39. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
